
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group is experiencing market share loss and pricing pressure from potential competition in the organ transplant therapy market, as well as slowing growth in their OCS share and overall US end market growth. However, the potential upside from new partnerships, initiatives, and financials from their ENHANCE PART B and DENOVO programs may help improve investor sentiment and drive stock price rebound.
Bears say
TransMedics Group is facing challenges in its sales growth and market penetration, which may lead to a slowdown in revenue growth in the near future. Despite its innovative technology and multiple FDA approvals, the company's margins have decreased due to investments in future growth, potentially limiting earnings upside. Additionally, competition in the market may pose a risk to the company's current market share.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares